FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595829810> ?p ?o ?g. }

• W2595829810 endingPage "1368" @default.
• W2595829810 startingPage "1359" @default.
• W2595829810 abstract "Background: The type 2 component of the oral poliovirus vaccine is targeted for global withdrawal through a switch from the trivalent oral poliovirus vaccine (tOPV) to a bivalent oral poliovirus vaccine (bOPV). The switch is intended to prevent paralytic polio caused by circulating vaccine-derived poliovirus type 2. We aimed to assess the immunogenicity and safety profile of 6 vaccination schedules with different sequential doses of inactivated poliovirus vaccine (IPV), tOPV, or bOPV.Methods: A randomized controlled trial was conducted in China in 2015. Healthy newborn babies randomly received one of the following 6 vaccination schedules: cIPV-bOPV-bOPV(I-B-B), cIPV-tOPV-tOPV(I-T-T), cIPV-cIPV-bOPV(I-I-B), cIPV-cIPV-tOPV(I-I-T), cIPV-cIPV-cIPV(I-I-I), or tOPV-tOPV-tOPV(T-T-T). Doses were administered sequentially at 4–6 week intervals after collecting baseline blood samples. Patients were proactively followed up for observation of adverse events after the first dose and 30 days after all doses. The primary study objective was to investigate the immunogenicity and safety profile of different vaccine schedules, evaluated by seroconversion, seroprotection and antibody titer against poliovirus types 1, 2, and 3 in the per-protocol population.Results: Of 600 newborn babies enrolled, 504 (84.0%) were included in the per-protocol population. For type 1 poliovirus, the differences in the seroconversion were 1.17% (95% CI = −2.74%, 5.08%) between I-B-B and I-T-T and 0.00% (95% CI: −6.99%, 6.99%) between I-I-B and I-I-T; for type 3 poliovirus, differences in the seroconversion were 3.49% (95% CI: −1.50%, 8.48%) between I-B-B and I-T-T and −2.32% (95% CI: −5.51%, 0.86%) between I-I-B and I-I-T. The non-inferiority conclusion was achieved in both poliovirus type 1 and 3 with the margin of −10%. Of 24 serious adverse events reported, no one was vaccine-related.Conclusions: The vaccination schedules with bOPV followed by one or 2 doses of IPV were recommended to substitute for vaccinations involving tOPV without compromising the immunogenicity and safety in the Chinese population. The findings will be essential for policy formulation by national and global authorities to facilitate polio elimination." @default.
• W2595829810 created "2017-03-23" @default.
• W2595829810 creator A5008599693 @default.
• W2595829810 creator A5009616039 @default.
• W2595829810 creator A5026394330 @default.
• W2595829810 creator A5043354763 @default.
• W2595829810 creator A5046597133 @default.
• W2595829810 creator A5063056426 @default.
• W2595829810 creator A5070873306 @default.
• W2595829810 creator A5077220004 @default.
• W2595829810 creator A5079523968 @default.
• W2595829810 creator A5082553860 @default.
• W2595829810 creator A5082780666 @default.
• W2595829810 creator A5083189754 @default.
• W2595829810 creator A5088985343 @default.
• W2595829810 date "2017-03-31" @default.
• W2595829810 modified "2023-09-29" @default.
• W2595829810 title "Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial" @default.
• W2595829810 cites W1528516601 @default.
• W2595829810 cites W1759712413 @default.
• W2595829810 cites W1977714159 @default.
• W2595829810 cites W2012518985 @default.
• W2595829810 cites W2015357954 @default.
• W2595829810 cites W2052818607 @default.
• W2595829810 cites W2103683759 @default.
• W2595829810 cites W2107376649 @default.
• W2595829810 cites W2117691753 @default.
• W2595829810 cites W2137591261 @default.
• W2595829810 cites W2142317414 @default.
• W2595829810 cites W2143963024 @default.
• W2595829810 cites W2146428253 @default.
• W2595829810 cites W2169817003 @default.
• W2595829810 cites W2171567692 @default.
• W2595829810 cites W2176372602 @default.
• W2595829810 cites W2196133620 @default.
• W2595829810 cites W2199228583 @default.
• W2595829810 cites W2209580910 @default.
• W2595829810 cites W2269774938 @default.
• W2595829810 cites W2311686760 @default.
• W2595829810 cites W2317436455 @default.
• W2595829810 cites W2364126779 @default.
• W2595829810 cites W2395273997 @default.
• W2595829810 cites W2497248970 @default.
• W2595829810 cites W2510158554 @default.
• W2595829810 cites W2552088616 @default.
• W2595829810 cites W2915372288 @default.
• W2595829810 cites W4292498372 @default.
• W2595829810 cites W4292578085 @default.
• W2595829810 doi "https://doi.org/10.1080/21645515.2017.1288769" @default.
• W2595829810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5489289" @default.
• W2595829810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28362135" @default.
• W2595829810 hasPublicationYear "2017" @default.
• W2595829810 type Work @default.
• W2595829810 sameAs 2595829810 @default.
• W2595829810 citedByCount "11" @default.
• W2595829810 countsByYear W25958298102018 @default.
• W2595829810 countsByYear W25958298102019 @default.
• W2595829810 countsByYear W25958298102020 @default.
• W2595829810 countsByYear W25958298102021 @default.
• W2595829810 countsByYear W25958298102022 @default.
• W2595829810 countsByYear W25958298102023 @default.
• W2595829810 crossrefType "journal-article" @default.
• W2595829810 hasAuthorship W2595829810A5008599693 @default.
• W2595829810 hasAuthorship W2595829810A5009616039 @default.
• W2595829810 hasAuthorship W2595829810A5026394330 @default.
• W2595829810 hasAuthorship W2595829810A5043354763 @default.
• W2595829810 hasAuthorship W2595829810A5046597133 @default.
• W2595829810 hasAuthorship W2595829810A5063056426 @default.
• W2595829810 hasAuthorship W2595829810A5070873306 @default.
• W2595829810 hasAuthorship W2595829810A5077220004 @default.
• W2595829810 hasAuthorship W2595829810A5079523968 @default.
• W2595829810 hasAuthorship W2595829810A5082553860 @default.
• W2595829810 hasAuthorship W2595829810A5082780666 @default.
• W2595829810 hasAuthorship W2595829810A5083189754 @default.
• W2595829810 hasAuthorship W2595829810A5088985343 @default.
• W2595829810 hasBestOaLocation W25958298101 @default.
• W2595829810 hasConcept C126322002 @default.
• W2595829810 hasConcept C141071460 @default.
• W2595829810 hasConcept C159047783 @default.
• W2595829810 hasConcept C159654299 @default.
• W2595829810 hasConcept C168563851 @default.
• W2595829810 hasConcept C187212893 @default.
• W2595829810 hasConcept C197934379 @default.
• W2595829810 hasConcept C203014093 @default.
• W2595829810 hasConcept C22070199 @default.
• W2595829810 hasConcept C2522874641 @default.
• W2595829810 hasConcept C2777451964 @default.
• W2595829810 hasConcept C2779631682 @default.
• W2595829810 hasConcept C2780868878 @default.
• W2595829810 hasConcept C2908647359 @default.
• W2595829810 hasConcept C2908689829 @default.
• W2595829810 hasConcept C4870876 @default.
• W2595829810 hasConcept C535046627 @default.
• W2595829810 hasConcept C71924100 @default.
• W2595829810 hasConcept C99454951 @default.
• W2595829810 hasConceptScore W2595829810C126322002 @default.
• W2595829810 hasConceptScore W2595829810C141071460 @default.
• W2595829810 hasConceptScore W2595829810C159047783 @default.

• next